TTRX - Turn Therapeutics Inc.
3.35
-0.030 -0.896%
Share volume: 25,791
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$3.38
-0.03
-0.01%
Fundamental analysis
39%
Profitability
35%
Dept financing
40%
Liquidity
50%
Performance
40%
Performance
5 Days
-1.17%
1 Month
-1.17%
3 Months
-27.16%
6 Months
-28.69%
1 Year
-51.71%
2 Year
-51.71%
Key data
Stock price
$3.35
DAY RANGE
$3.20 - $3.44
52 WEEK RANGE
$2.57 - $26.50
52 WEEK CHANGE
-$51.71
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Bradley Burnam
Region: US
Website: turntherapeutics.com/
Employees: 2
IPO year: 2025
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: turntherapeutics.com/
Employees: 2
IPO year: 2025
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™, enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. Our principal executive offices are located in Westlake Village, CA.
Recent news